公开(公告)号：WO2012007965A1

公开(公告)日：2012-01-19

申请号：PCT/IN2011/000469

申请日：2011-07-14

Applicant: CADILA HEALTHCARE LIMITED ,  JOSHI, Rupal ,  NAIR, Anita ,  RAMRAKHIANI, Anita ,  MENDIRATTA, Sanjeev, Kumar ,  TRIVEDI, Umang

Inventor： JOSHI, Rupal ,  TRIVEDI, Umang

IPC: C12P17/12 ,  C12N15/53 ,  C12N9/02 ,  C12P21/02 ,  C12N9/04

CPC classification number: C12P17/182 ,  C12N9/0004 ,  C12N9/0006 ,  C12N9/0008 ,  C12P17/12 ,  C12P41/002 ,  C12R1/19 ,  C12Y101/01047 ,  Y02P20/52

Abstract: The present invention provides a process for production of optically pure quinuclidinol of formula-(I) by reduction of quinuclidinone of formula-(Il) in presence of suitable oxidoreductase enzyme derived from Saccharomyces species . Formula (II, I) Moreover, the present enzyme works in presence of cofactor NADP where the cofactor is regenerated by suitable system. The present invention also provides a recombinant vector containing genes co expressing suitable polypeptides having oxido-reductase activity and polypeptide having capacity to regenerate the co-factor. The said vector is transformed in suitable host cell.

Abstract translation: 本发明提供了在衍生自酵母属物种的合适的氧化还原酶存在下通过还原式（II）的奎宁环酮来制备式（I）的光学纯奎宁环醇的方法。 式（II，I）此外，本发明酶在辅因子NADP的存在下起作用，其中辅因子通过合适的系统再生。 本发明还提供了含有表达具有氧化还原酶活性的合适多肽的基因的重组载体和具有再生辅助因子能力的多肽。 所述载体在合适的宿主细胞中转化。

公开(公告)号：WO2008107908A1

公开(公告)日：2008-09-12

申请号：PCT/IN2008/000114

申请日：2008-02-29

Applicant: CADILA HEALTHCARE LIMITED ,  BANDYOPADHYAY, Sanjay ,  MENDIRATTA, Sanjeev, Kumar ,  NATARAJAN, Venkatesan ,  PATEL, Pankaj, Ramanbhai

Inventor： BANDYOPADHYAY, Sanjay ,  MENDIRATTA, Sanjeev, Kumar ,  NATARAJAN, Venkatesan ,  PATEL, Pankaj, Ramanbhai

IPC: A61K9/19 ,  A61K9/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K9/00 ,  A61K38/00 ,  A61K47/48

CPC classification number: A61K9/19 ,  A61K9/0019 ,  A61K9/08 ,  A61K38/212 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  A61K47/60 ,  A61K47/6921

Abstract: The present invention relates to novel lyophilized and stabilized formulations of PEG-interferon alpha conjugates and the process for their preparation. The novel formulations of PEG-interferon alpha conjugates reported by the inventors of this application require shorter lyophilization cycle and are more cost competitive.

Abstract translation: 本发明涉及PEG-干扰素α缀合物的新型冻干和稳定制剂及其制备方法。 由本申请的发明人报道的PEG-干扰素α缀合物的新型制剂需要更短的冻干周期，并且更具成本竞争力。

公开(公告)号：WO2005009407A3

公开(公告)日：2006-03-02

申请号：PCT/IB2004051335

申请日：2004-07-29

Applicant: RANBAXY LAB LTD ,  DUBEY VIVEK MAHENDRAKUMAR ,  DESHMUKH ABHIJIT MUKUND ,  SETHI SANJEEV KUMAR ,  MALIK RAJIV

Inventor： DUBEY VIVEK MAHENDRAKUMAR ,  DESHMUKH ABHIJIT MUKUND ,  SETHI SANJEEV KUMAR ,  MALIK RAJIV

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/26 ,  A61K9/28 ,  A61K9/50 ,  A61K31/551

CPC classification number: A61K9/1623 ,  A61K9/1652 ,  A61K9/2077 ,  A61K9/2813 ,  A61K9/284 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/5015 ,  A61K31/551

Abstract: The present invention relates to olanzapine formulations stable to discoloration. The pharmaceutical formulations include olanzapine particles or powder, and a coating on the olanzapine particles or powder. The coating includes lactose and/or mannitol and optionally one or more pharmaceutically acceptable excipients.

Abstract translation: 本发明涉及对变色稳定的奥氮平制剂。 药物制剂包括奥氮平颗粒或粉末，以及奥氮平颗粒或粉末上的涂层。 该涂层包括乳糖和/或甘露醇和任选的一种或多种药学上可接受的赋形剂。

公开(公告)号：WO2005063219A3

公开(公告)日：2005-08-11

申请号：PCT/IB2004004185

申请日：2004-12-17

Applicant: RANBAXY LAB LTD ,  DUBEY VIVEK MAHENDRAKUMAR ,  RAO VISINGIRI VENKAT RAM MOHAN ,  DESHMUKH ABHIJIT MUKUND ,  SETHI SANJEEV KUMAR

Inventor： DUBEY VIVEK MAHENDRAKUMAR ,  RAO VISINGIRI VENKAT RAM MOHAN ,  DESHMUKH ABHIJIT MUKUND ,  SETHI SANJEEV KUMAR

IPC: A61K9/48 ,  A61K31/192

CPC classification number: A61K9/4866 ,  A61K31/192

Abstract: The invention relates to ibuprofen-containing soft gelatin capsules, pharmaceutical compositions of a substantially clear ibuprofen solution, and process for their manufacture. It also relates to pharmaceutical compositions of substantially clear solutions containing ibuprofen and pseudoephedrine and use of such compositions for treatment of common cold and flu-like symptoms.

Abstract translation: 本发明涉及含布洛芬的软明胶胶囊，基本上清楚的布洛芬溶液的药物组合物及其制造方法。 它还涉及含有布洛芬和伪麻黄碱的基本上澄清的溶液的药物组合物，以及这种组合物用于治疗普通感冒和流感样症状的用途。

公开(公告)号：WO2005070442A1

公开(公告)日：2005-08-04

申请号：PCT/IB2003/006106

申请日：2003-12-22

Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH ,  PUSHPANGADAN, Palpu ,  MEHROTRA, Shanta ,  RAO, Chandana, Venkateswara ,  OJHA, Sanjeev, Kumar ,  RAGHAVAN, Govindarajan ,  RAO, Guntupalli, Madan, Mohana ,  SREEDEVI, Padmavathi

Inventor： PUSHPANGADAN, Palpu ,  MEHROTRA, Shanta ,  RAO, Chandana, Venkateswara ,  OJHA, Sanjeev, Kumar ,  RAGHAVAN, Govindarajan ,  RAO, Guntupalli, Madan, Mohana ,  SREEDEVI, Padmavathi

IPC: A61K35/78

CPC classification number: A61K36/88 ,  A61K36/515 ,  A61K36/75 ,  A61K36/9068 ,  Y10S514/824 ,  Y10S514/909 ,  A61K2300/00

Abstract: The present invention relates to a synergistic pharmaceutical composition useful for the treatment of hyperlipidemia, said composition comprising extracts of plant Gentiana kurroo of concentration ranging between 2-5 wt. %, Murraya koenigii of concentration ranging between 8-15wt %, Allium sativum of concentration ranging between 2-4 wt %, Zingiber officinalis of concentration ranging between 2-5wt %, Amorphophallus campanulatus of concentration ranging between 1-10%, and pharmaceutically acceptable additive(s); a process for the preparation of the said synergistic pharmaceutical composition; and also, a use of the said composition for treating hyperlipidemia, atherosclerosis, and obesity.

Abstract translation: 本发明涉及可用于治疗高脂血症的协同药物组合物，所述组合物包含浓度范围在2-5wt。之间的植物龙胆草提取物。 ％，浓度范围在8-15wt％之间的Murraya koenigii，浓度范围在2-4wt％之间的浓缩枸杞子，浓度范围在2-5wt％之间，浓度范围在1-10％之间的orpho，，和药学上可接受的 添加剂; 用于制备所述协同药物组合物的方法; 以及所述组合物用于治疗高脂血症，动脉粥样硬化和肥胖症的用途。

公开(公告)号：WO2005063219A2

公开(公告)日：2005-07-14

申请号：PCT/IB2004/004185

申请日：2004-12-17

Applicant: RANBAXY LABORATORIES LIMITED ,  DUBEY, Vivek, Mahendrakumar ,  RAO, Visingiri, Venkat, Ram, Mohan ,  DESHMUKH, Abhijit, Mukund ,  SETHI, Sanjeev, Kumar

Inventor： DUBEY, Vivek, Mahendrakumar ,  RAO, Visingiri, Venkat, Ram, Mohan ,  DESHMUKH, Abhijit, Mukund ,  SETHI, Sanjeev, Kumar

IPC: A61K31/00

CPC classification number: A61K9/4866 ,  A61K31/192

Abstract: The invention relates to ibuprofen-containing soft gelatin capsules, pharmaceutical compositions of a substantially clear ibuprofen solution, and process for their manufacture. It also relates to pharmaceutical compositions of substantially clear solutions containing ibuprofen and pseudoephedrine and use of such compositions for treatment of common cold and flu-like symptoms.

Abstract translation: 本发明涉及含有布洛芬的软明胶胶囊，基本上清楚的布洛芬溶液的药物组合物及其制造方法。 它还涉及含有布洛芬和伪麻黄碱的基本上清澈的溶液的药物组合物，以及这些组合物用于治疗感冒和流感样症状的药物组合物。

公开(公告)号：WO2005063186A1

公开(公告)日：2005-07-14

申请号：PCT/IN2003/000417

申请日：2003-12-30

Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH ,  PUSHPANGADAN, Palpu ,  RAO, Chandana, Venkateswara ,  OJHA, Sanjeev, Kumar ,  NAIR, Kuttan, Pillai, Narayanan ,  PANDEY, Madan, Mohan ,  RAWAT, Ajay, Kumar, Singh ,  MEHROTRA, Shanta

Inventor： PUSHPANGADAN, Palpu ,  RAO, Chandana, Venkateswara ,  OJHA, Sanjeev, Kumar ,  NAIR, Kuttan, Pillai, Narayanan ,  PANDEY, Madan, Mohan ,  RAWAT, Ajay, Kumar, Singh ,  MEHROTRA, Shanta

IPC: A61K7/26

CPC classification number: A61Q11/00 ,  A61K8/97 ,  A61K36/58 ,  A61K36/752 ,  A61K36/758 ,  A61K36/88 ,  Y10S514/90 ,  Y10S514/901 ,  Y10S514/902 ,  A61K2300/00

Abstract: This invention relates to novel dental compositions and methods for preventing dental plaque and caries formation and generally for inhibiting tooth decay and brightening/whitening teeth/mouth ulcer. The compositions of this invention comprise herbs such as Citrus karna raf., Zanthoxylum armatum D.C. and Azadirachta indica A. Juss. there of which can be combined with pharmaceutically acceptable carriers or diluents to be administered in the form of conventional dental compositions. The compositions of the present invention also preferably contain Mint.

Abstract translation: 本发明涉及用于预防牙斑和龋齿形成的新型牙科用组合物和方法，通常用于抑制蛀牙和增白/增白牙齿/口腔溃疡。 本发明的组合物包括草本植物，例如柑橘猕猴桃，花椒（Zanthoxylum armatum D.C.）和楝树（Azadirachta indica A.Juss）。 其中可与可药用载体或稀释剂组合以常规牙科组合物的形式施用。 本发明的组合物还优选含有薄荷醇。

公开(公告)号：WO2005016315A1

公开(公告)日：2005-02-24

申请号：PCT/IB2004/002654

申请日：2004-08-13

Applicant: RANBAXY LABORATORIES LIMITED ,  SINGH, Romi, Barat ,  SHILPA, Anu ,  NAGAPRASAD, Vishnubhotla ,  SETHI, Sanjeev, Kumar

Inventor： SINGH, Romi, Barat ,  SHILPA, Anu ,  NAGAPRASAD, Vishnubhotla ,  SETHI, Sanjeev, Kumar

IPC: A61K9/20

CPC classification number: A61K31/00 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054

Abstract: The present invention relates to pharmaceutical compositions of Nateglinide with 50-70% of water-soluble filler such as lactose alone or in combination with a channeling agent such as sodium chloride or compressible sugar. These compositions may have a dissolution profile wherein at least 70% by weight of Nateglinide is released within 45 minute period.

Abstract translation: 本发明涉及那格列奈的药物组合物，其具有50-70％的水溶性填料，例如单独的乳糖或与窜流剂如氯化钠或可压缩糖组合。 这些组合物可具有溶解曲线，其中至少70重量％的那格列奈在45分钟内释放。

公开(公告)号：WO2005002592A2

公开(公告)日：2005-01-13

申请号：PCT/IB2004/002191

申请日：2004-07-01

Applicant: RANBAXY LABORATORIES LIMITED ,  METHA, Kamal ,  MATHUR, Rajeev, Shankar ,  PAUL, Sujata ,  SETHI, Sanjeev, Kumar ,  MALIK, Rajiv

Inventor： METHA, Kamal ,  MATHUR, Rajeev, Shankar ,  PAUL, Sujata ,  SETHI, Sanjeev, Kumar ,  MALIK, Rajiv

IPC: A61K31/70

CPC classification number: A61K9/0095 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K31/70

Abstract: The present invention relates to stable oral compositions of azithromycin monohydrate with reduced bitterness, processes for making these compositions, and methods of using these compositions for the treatment of microbial infections. The stable oral compositions of azithromycin include an azithromycin premix, at least one pharmaceutically accepted excipient, and, optionally, at least one taste-masking agent. The azithromycin premix includes azithromycin monohydrate and at least one additive.

Abstract translation: 本发明涉及具有降低的苦味的阿奇霉素一水合物的稳定口服组合物，以及制备这些组合物的方法，以及使用这些组合物治疗微生物感染的方法。 阿奇霉素的稳定的口服组合物包括阿奇霉素预混物，至少一种药学上可接受的赋形剂和任选的至少一种掩味剂。 阿奇霉素预混物包括阿奇霉素一水合物和至少一种添加剂。

公开(公告)号：WO2012046255A3

公开(公告)日：2012-05-31

申请号：PCT/IN2011000703

申请日：2011-10-10

Applicant: CADILA HEALTHCARE LTD ,  PARIKH AASHINI ,  SINGH ARUN ,  MENDIRATTA SANJEEV KUMAR ,  GUPTA AJIT K ,  JAKHADE MANSI

Inventor： PARIKH AASHINI ,  SINGH ARUN ,  GUPTA AJIT K ,  JAKHADE MANSI

IPC: C12N15/85

CPC classification number: C12N15/85 ,  C12N9/6459 ,  C12N15/68 ,  C12N2830/42 ,  C12N2830/46 ,  C12N2840/203 ,  C12P21/00 ,  C12Y304/21069

Abstract: The present invention provides an expression vector for the production of proteins and peptides comprising a promoter operably linked to gene of interest, TPL and VA genes I and II, matrix attachment regions (MARs)/SARs, antibiotic marker. The said vector is transfected in suitable host cell.

Abstract translation: 本发明提供了用于产生蛋白质和肽的表达载体，所述表达载体包含与感兴趣基因，TPL和VA基因I和II，基质附着区（MARs）/ SARs，抗生素标记物可操作连接的启动子。 将所述载体转染至合适的宿主细胞中。